Cell-free DNA Analysis for Noninvasive Examination of Trisomy
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cell-free DNA (cfDNA) testing for fetal trisomy is highly effective among high-risk women. However, there have been few direct, well-powered studies comparing cfDNA testing with standard screening during the first trimester in routine prenatal populations. METHODS: In this prospective, multicenter, blinded study conducted at 35 international centers, we assigned pregnant women presenting for aneuploidy screening at 10 to 14 weeks of gestation to undergo both standard screening (with measurement of nuchal translucency and biochemical analytes) and cfDNA testing. Participants received the results of standard screening; the results of cfDNA testing were blinded. Determination of the birth outcome was based on diagnostic genetic testing or newborn examination. The primary outcome was the area under the receiver-operating-characteristic curve (AUC) for trisomy 21 (Down's syndrome) with cfDNA testing versus standard screening. We also evaluated cfDNA testing and standard screening to assess the risk of trisomies 18 and 13. RESULTS: Of 18,955 women who were enrolled, results from 15,841 were available for analysis. The mean maternal age was 30.7 years, and the mean gestational age at testing was 12.5 weeks. The AUC for trisomy 21 was 0.999 for cfDNA testing and 0.958 for standard screening (P=0.001). Trisomy 21 was detected in 38 of 38 women (100%; 95% confidence interval [CI], 90.7 to 100) in the cfDNA-testing group, as compared with 30 of 38 women (78.9%; 95% CI, 62.7 to 90.4) in the standard-screening group (P=0.008). False positive rates were 0.06% (95% CI, 0.03 to 0.11) in the cfDNA group and 5.4% (95% CI, 5.1 to 5.8) in the standard-screening group (P<0.001). The positive predictive value for cfDNA testing was 80.9% (95% CI, 66.7 to 90.9), as compared with 3.4% (95% CI, 2.3 to 4.8) for standard screening (P<0.001). CONCLUSIONS: In this large, routine prenatal-screening population, cfDNA testing for trisomy 21 had higher sensitivity, a lower false positive rate, and higher positive predictive value than did standard screening with the measurement of nuchal translucency and biochemical analytes. (Funded by Ariosa Diagnostics and Perinatal Quality Foundation; NEXT ClinicalTrials.gov number, NCT01511458.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, cfDNA analysis has been useful for non-invasive prenatal testing applications, such as for the identification of trisomy 21 (ref.124).”
From Clinical metagenomics (2019) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome
Malone, F. D., Canick, J. A., Ball, R. H., Nyberg, D. A., Comstock, C. H., Bukowski, R., Berkowitz, R. L., Gross, S. J., Dugoff, L., Craigo, S. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043693 · Cited by 1,081
Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., Ehrich, M., van den Boom, D., Bombard, A. T., Deciu, C., Grody, W. W., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182368a0e · Cited by 939
Gil, M. M., Quezada, M. S., Revello, R., Akolekar, R., & Nicolaides, K. H. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14791 · Cited by 807
Akolekar, R., Beta, J., Picciarelli, G., Ogilvie, C., & D'Antonio, F. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14636 · Cited by 711
Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population
Nicolaides, K. H., Syngelaki, A., Ashoor, G., Birdir, C., & Touzet, G. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.08.033 · Cited by 624
DNA Sequencing versus Standard Prenatal Aneuploidy Screening
Bianchi, D. W., Parker, R. L., Wentworth, J., Madankumar, R., Saffer, C., Das, A. F., Craig, J. A., Chudova, D. I., Devers, P. L., Jones, K. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311037 · Cited by 620
Norton, M. E., Brar, H., Weiss, J., Karimi, A., Laurent, L. C., Caughey, A. B., Rodriguez, M. H., Williams, J., Mitchell, M. E., Adair, C. D., et al. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.05.021 · Cited by 596
Self-citationFirst-Trimester Screening for Trisomies 21 and 18
Wapner, R., Thom, E., Simpson, J. L., Pergament, E., Silver, R., Filkins, K., Platt, L., Mahoney, M., Johnson, A., Hogge, W. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025273 · Cited by 563
Self-citationDNA Sequencing Versus Standard Prenatal Aneuploidy Screening
Rochon, M. L. (2014) · Cited by 468
Cited by
Items 501–600 of 817
Yang, L., Xu, Y., Xia, J., Yan, H., Ding, C., Shi, Q., Wu, Y., Liu, P., Pan, J., Zeng, Y., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.976131 · Cited by 4
Seminal cell-free nucleic acids as possible biomarker in male infertility: a mini-review article
Javidmehr, D., Fesahat, F., Hassani, F., Talebi, A. R., & Shahverdi, A. (2024) · African Journal of Urology · doi:10.1186/s12301-024-00450-1 · Cited by 4
Updates and Knowledge Gaps in Placenta Accreta Spectrum Biology
Ligumsky, L. K., Scott, O., Martínez, G., Jeong, A., Yin, O., Shah, S., Wang, A., Zhu, Y., & Afshar, Y. (2025) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000929 · Cited by 6
Residual risk of noninvasive prenatal screening in pregnancies with ultrasound anomalies
Lu, B., Yin, L., Wang, J., Yu, B., & Zhang, B. (2022) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2022.102515 · Cited by 4
Cell-free DNA in large B-cell lymphoma: MRD and beyond
Sworder, B. J., & Kurtz, D. M. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.06.004 · Cited by 4
Liang, D., Lin, Y., Luo, C., Li, H., Hu, P., & Xu, Z. (2024) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2479 · Cited by 4
Cell‐free DNA test for fetal chromosomal abnormalities in multiple pregnancies
Kwan, A. H. W., Gil, M. M., Xue, S., Kwok, Y. K. Y., Lau, D., Fung, J. C. Y., Chan, A., Choy, K. W., Leung, T. Y., & Poon, L. C. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14901 · Cited by 5
Molecular Diagnostics in Pediatric Pathology Practice
Surrey, L. F., Church, A. J., & Nelson, N. D. (2024) · Surgical pathology clinics · doi:10.1016/j.path.2024.11.007 · Cited by 4
Incidental Detection of Maternal Cancer Following Cell-Free DNA Screening for Fetal Aneuploidies
Goldlust, I. S., & Bianchi, D. W. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvae170 · Cited by 4
Emahazion, T., Badri, A., Jalkesten, E., Flodström‐Tullberg, M., Ajne, G., Uzunel, M., & Wikman, A. T. (2025) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2025.101694 · Cited by 4
Advantages of the single nucleotide polymorphism-based noninvasive prenatal test
Kim, K. (2015) · Journal of genetic medicine · doi:10.5734/jgm.2015.12.2.66 · Cited by 4
Prenatal diagnosis of trisomy 21, 18 and 13 by quantitative pyrosequencing of segmental duplications
Tong, H., Jin, Y., Xu, Y., Zou, B., Ye, H., Wu, H., Kumar, S., Pitman, J. L., Zhou, G., & Song, Q. (2016) · Clinical Genetics · doi:10.1111/cge.12772 · Cited by 4
Prenatal screening costs at a large military treatment facility
Shiv, E., Sale, T. J., Simsiman, A. J., Leininger, W. M., & Lutgendorf, M. A. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1214702 · Cited by 4
Application of Differentially Methylated Loci in Clinical Diagnosis of Trisomy 21 Syndrome
Zhang, R., Yin, Y., Zhang, S., Chen, L., Li, P., Deng, Q., Zhang, H., & Li, X. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0176 · Cited by 4
Prenatal Diagnosis of Chromosome Abnormalities
Bilancia, C. G., Ganapathi, M., & Levy, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-7020-6956-7.00024-5 · Cited by 6
Challenges in health technology assessments of genetic tests
Xie, X., Gajic‐Veljanoski, O., Falk, L., Schaink, A. K., Lambrinos, A., Wang, M., Ng, V., Ungar, W. J., & Sikich, N. (2020) · Journal of Hospital Management and Health Policy · doi:10.21037/jhmhp-20-47 · Cited by 7
Xu, Y., Jin, P., Lei, Y., Qian, Y., Xu, Y., Wang, M., Jin, J., Yin, Y., & Dong, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.661884 · Cited by 4
Jing, X., Liu, H., Zhu, Q., Liu, S., Liu, J., Bai, T., Deng, C., Xia, T., Liu, Y., Cheng, J., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.811414 · Cited by 4
Yang, C., Hu, L., Jiang, S., Liang, F., & Zhang, S. (2022) · Medicine · doi:10.1097/md.0000000000029985 · Cited by 5
Comparing Non-invasive Prenatal Testing With Invasive Testing for the Detection of Trisomy 21
Mokhtar, R., Hans, P., & Sinha, A. (2022) · Cureus · doi:10.7759/cureus.31252 · Cited by 5
A new contingent screening strategy increased detection rate of trisomy 21 in the first trimester
Luo, W. P., He, B., Han, D., Yuan, L., Tang, J., Pang, L., Zou, F., Zhao, K., Liu, S., & Hu, T. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-06115-1 · Cited by 4
Lewkowitz, A. K., Kaimal, A. J., Thao, K., O’Leary, A., Nseyo, O., & Kuppermann, M. (2017) · Journal of Perinatology · doi:10.1038/jp.2017.66 · Cited by 4
Contemporary Evaluation of the Neonate with Congenital Anomalies
Wenger, T. L., & Bhoj, E. J. K. (2017) · NeoReviews · doi:10.1542/neo.18-9-e522 · Cited by 4
A new tool to assess understanding of Down syndrome screening information presented by midwives
John, S., Kirk, M., Tonkin, E. T., & Stuart‐Hamilton, I. (2019) · British Journal of Midwifery · doi:10.12968/bjom.2019.27.11.694 · Cited by 4
Pregnant women's preferences for prenatal genetic testing: A single‐center study in Japan
Shibata, M., Akaishi, R., Sasaki, A., Ogawa, K., Nishiyama, M., Wada, S., Ozawa, N., & Sago, H. (2020) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14381 · Cited by 4
Diagnostic value of cfDNA and long fragment DNA in patients with breast cancer
Xu, H., & Liu, G. (2020) · Cellular and Molecular Biology · doi:10.14715/cmb/2020.66.7.28 · Cited by 4
Crimmins, S. D., Doyle, L. E., Slejko, J. F., Kopelman, J. N., & Turan, O. M. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1247800 · Cited by 4
A Paradigm Shift: Considerations in Prenatal Cell-Free DNA Screening
Dines, J. N., Eckel, A. M., Cheng, E. Y., & Lockwood, C. M. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2017.023119 · Cited by 4
Screening for Fetal Chromosome Abnormalities
McCathern, B. C., Longman, R. E., & Abramowicz, J. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-24133-8_9 · Cited by 4
Fetal screening and whole genome sequencing: where are the limits?
Hancock, S. E., Taber, K. J., & Goldberg, J. D. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1919087 · Cited by 4
Impact of Structural Differences on the Modeled Cost-Effectiveness of Noninvasive Prenatal Testing
Salisbury, A., Pearce, A. M., Howard, K., & Norris, S. (2024) · Medical Decision Making · doi:10.1177/0272989x241263368 · Cited by 3
Jian, H., Zhang, C., Zeng, L., Wang, T., Yi, M., & Song, J. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70722 · Cited by 3
Cell-free DNA Screening for Aneuploidy
Norton, M. E. (2023) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000796 · Cited by 4
Self-citationNoninvasive Prenatal Testing Using Fetal Fraction Enrichment—A Pilot Study
Chen, Y., Lai, Y., Yi, J., Yi, S., Huang, X., Tang, Y., Su, J., Shen, Y., & Wei, H. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5105114 · Cited by 4
Performance of cell free DNA as a screening tool based on the results of first trimester screening
Motevasselian, M., Omrani, M. A., Gargari, S. S., Younesi, S., Amin, M. M. T., Saadati, P., Jamali, S., Modarresi, M., Savad, S., Rahmani, M., et al. (2024) · Molecular Cytogenetics · doi:10.1186/s13039-024-00702-3 · Cited by 4
Prenatal Screening for Chromosomal Defects
Frisová, V. (2025) · Reproductive Medicine · doi:10.3390/reprodmed6020015 · Cited by 9
Han, S., Yang, Y. H., Ryu, J.-S., Kang, M.-S., Kim, Y. J., & Lee, K.-R. (2015) · Journal of genetic medicine · doi:10.5734/jgm.2015.12.2.85 · Cited by 3
Canadian women’s attitudes toward noninvasive prenatal testing of fetal DNA in maternal plasma*
Pariente, G., Hasan, L., Gadot, Y., Souza, L. R. D., Lebovic, G., & Berger, H. M. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2016.1152253 · Cited by 5
Nichtinvasive pränatale Tests in der Zukunft
Schmid, M. (2016) · Der Gynäkologe · doi:10.1007/s00129-016-3883-4 · Cited by 3
Trends in Fetal Medicine: A 10-Year Bibliometric Analysis of Prenatal Diagnosis
Dhombres, F., & Bodenreider, O. (2017) · Studies in health technology and informatics · doi:10.3233/978-1-61499-830-3-853 · Cited by 3
Grati, F. R., Bajaj, K., Simoni, G., Maggi, F., Gross, S. J., & Ferreira, J. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813570-9.00028-0 · Cited by 3
Lau, T. K., Zhu, X., Kwok, Y. K. Y., Leung, T. Y., & Choy, K. W. (2020) · Journal of Fetal Medicine · doi:10.1007/s40556-019-00229-3 · Cited by 3
Non-invasive prenatal screening for fetal aneuploidy in twin pregnancies by cell-free DNA analysis
Chen, Y., Lai, Y., Yi, S., Tang, Y., Lei, Y., Yi, S., Shen, Y., & Wei, H. (2018) · Clinical and Experimental Obstetrics & Gynecology · doi:10.12891/ceog4242.2018 · Cited by 3
Carlsson, Y., Strömbäck, P., & Lundgren, I. (2021) · Sexual & Reproductive Healthcare · doi:10.1016/j.srhc.2021.100652 · Cited by 4
Genovese, G., Mello, C. J., Loh, P., Handsaker, R. E., Kashin, S., Whelan, C. W., Bayer-Zwirello, L. A., & McCarroll, S. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-14049-5 · Cited by 4
Cell-free DNA screening in twin pregnancies
Boo, H. Y., & Han, Y. J. (2024) · Obstetrics & Gynecology Science · doi:10.5468/ogs.23135 · Cited by 3
Salisbury, A., Norris, S., Pearce, A. M., & Howard, K. (2025) · Applied Health Economics and Health Policy · doi:10.1007/s40258-024-00938-5 · Cited by 3
McFadden, P. W., Smithson, S. D., Massaro, R., Huang, J., Prado, G. T., & Shertz, W. T. (2016) · Pediatric and Developmental Pathology · doi:10.2350/16-01-1765-cr.1 · Cited by 3
Anselem, O., Keroui, S., Deput-Rampon, C., Chartier, M., Costa, J., Goffinet, F., & Tsatsaris, V. (2016) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2015.12.006 · Cited by 3
Oraluck, P., Boonsong, O., Wasun, C., Ammarin, T., & Panyu, P. (2017) · Health Care Current Reviews · doi:10.4172/2375-4273.1000207 · Cited by 3
Cell-free DNA and contingent screening: Our first year
Gomes, H. H., Lourenço, I. O., Ribeiro, J., Martins, D., Ribeiro, R., & Francisco, C. (2019) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2019.04.001 · Cited by 3
NIPT Technique Based on the Use of Long Chimeric DNA Reads
Belova, V., Plakhina, D., Evfratov, S. A., Tsukanov, K., Khvorykh, G. V., Rakitko, A., Konoplyannikov, A., Ilinsky, V. V., Rebrikov, D. V., & Korostin, D. O. (2020) · Genes · doi:10.3390/genes11060590 · Cited by 3
Sherer, D. M., Hsieh, V., Hall, A., Gerren, A., Walters, E., & Dalloul, M. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s328201 · Cited by 3
Nichtinvasive pränatale Tests aus Sicht des Humangenetikers
Stümm, M. (2016) · Der Gynäkologe · doi:10.1007/s00129-016-3885-2 · Cited by 3
Current Concepts in Noninvasive Prenatal Screening (NIPS)
Leonard, S. P. (2017) · Journal of Fetal Medicine · doi:10.1007/s40556-017-0122-6 · Cited by 4
Luisa Fernanda Olaya, A., Hyett, J. A., & McLennan, S. V. (2017) · Prenatal Diagnosis · doi:10.1002/pd.5075 · Cited by 3
Bardy, C., Mattuizzi, A., Coatleven, F., Nithart, A., Evrard, G., Benachi, A., Nisand, I., & Sentilhes, L. (2017) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2017.11.002 · Cited by 4
Shirazi, M., Sarmadi, S., Niromanesh, S., Sharbaf, F. R., Sahebdel, B., Golshahi, F., Asadi, L., & Rahmanzadeh, M. (2019) · Journal of Obstetrics Gynecology and Cancer Research · doi:10.30699/jogcr.4.1.12 · Cited by 3
Balayla, J., & Shrem, G. (2020) · Journal of Pregnancy · doi:10.1155/2020/7801039 · Cited by 3
Wang, E. Y., Perni, U. C., & Gregg, A. R. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000677 · Cited by 3
T21: le TGNI peut éviter des amniocentèses illégitimes
(2015) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(15)30108-8 · Cited by 3
Cell-Free DNA Screening During Pregnancy
Cohen, A. W., & Westover, T. (2019) · JAMA · doi:10.1001/jama.2018.18644 · Cited by 3
Primary cell-free DNA screening or contingent screening for the common trisomies: a response
Dar, P., & Norton, M. E. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.02.025 · Cited by 3
Self-citationThe Art (and Science) of Individualized Selection of Non-Invasive Prenatal Screening (NIPS)
Hsieh, V., Sherer, D. M., Davydovych, K., Kheyman, M., & Dalloul, M. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s437214 · Cited by 2
Diurnal Effects on the Fraction of Fetal Cell‐Free DNA in Maternal Plasma
Gamisch, A., Hess, J., & Mustafa-Korninger, M. E. (2025) · Prenatal Diagnosis · doi:10.1002/pd.6836 · Cited by 2
Views and attitudes about the offer of NIPT: a qualitative study of UK healthcare professionals
Young, P. D., & Sahan, K. (2025) · BMC Medical Ethics · doi:10.1186/s12910-025-01227-z · Cited by 2
Jang, H., Park, J. E., Kim, H., Go, M., Yang, S. H., Kim, J. C., Eom, S., Park, H., Kim, S. H., Shim, S. H., et al. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08156-7 · Cited by 2
Li, Y., Liu, S., & Liu, H. (2025) · Journal of Computing and Electronic Information Management · doi:10.54097/dz3jjf38 · Cited by 2
Taneja, P. A., Snyder, H. L., de Feo, E., & Kruglyak, K. M. (2017) · Reproductive Endocrinology · doi:10.18370/2309-4117.2017.34.89-94 · Cited by 2
Unterscheider, J., & O’Donoghue, K. (2017) · Cambridge University Press eBooks · doi:10.1017/9781107585775.028 · Cited by 2
Johnson, K. A., & Catanzarite, V. A. (2021) · Clinics in Perinatology · doi:10.1016/j.clp.2021.05.007 · Cited by 2
Gilner, J. B., Rhee, E. H. J., Padro, A., & Kuller, J. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-65399-2.00011-5 · Cited by 3
Combined Model-Based Prediction for Non-Invasive Prenatal Screening
Yang, S.-Y., Kang, K. M., Kim, S., Lim, S. Y., Jang, H. Y., Hong, K., Cha, D. H., Shim, S. H., & Joung, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314990 · Cited by 2
Sadvakassova, L., Kurmangali, Z., Beloussov, V., Rakisheva, Z., & Terzic, M. (2023) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2023.2022-10-4 · Cited by 3
Noninvasive prenatal screening for fetal aneuploidies
Hasadsri, L., & Allyse, M. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00038-9 · Cited by 4
Xie, J., Jiang, Y. L., Zhou, Y., Jin, D., Lu, X., & Ge, Y. (2024) · Maternal-Fetal Medicine · doi:10.1097/fm9.0000000000000248 · Cited by 4
Liu, J., Wang, S., Zhou, S., Ma, D., Hu, L., Huang, H., Linpeng, S., Lin, J., Hong, L., Fu, Q., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1535381 · Cited by 5
The impact of preimplantation genetic testing for aneuploidy on prenatal screening
Gulersen, M., Peyser, A., Kim, J., Ferraro, A., Goldman, R. H., Mullin, C. M., Li, X., Krantz, D., Bornstein, E., & Rochelson, B. L. (2021) · Journal of Perinatal Medicine · doi:10.1515/jpm-2021-0495 · Cited by 2
Schmid, M., Klaritsch, P., Burkhardt, T., Duba, H., Haeusler, M. C. H., Hafner, E., Pertl, B., Speicher, M. R., Steiner, H., Tercanli, S., et al. (2015) · Cited by 2
DeMaio, A., Green, A., & Daly, S. (2016) · Prenatal Diagnosis · doi:10.1002/pd.4838 · Cited by 2
Prenatal screening for fetal aneuploidy: time to examine where we are and where we are going
Biggio, J. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.02.038 · Cited by 2
Modifying Risk of Aneuploidy with a Positive Cell-Free Fetal DNA Result
Long, A., Abuhamad, A., & Warsof, S. L. (2016) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2016.01.018 · Cited by 2
Harasim, T., Rost, I., & Klein, H. (2016) · Journal of Laboratory Medicine · doi:10.1515/labmed-2016-0038 · Cited by 2
Dupont, J., Simon‐Bouy, B., Zebina, A., Pessione, F., Royère, D., & Doco‐Fenzy, M. (2017) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2017.01.015 · Cited by 2
Shajpal, A., & Siddiqui, F. (2017) · Obstetrics Gynaecology & Reproductive Medicine · doi:10.1016/j.ogrm.2017.08.006 · Cited by 2
Scholl, J. E., & Chasen, S. T. (2018) · The Surgery Journal · doi:10.1055/s-0038-1624564 · Cited by 2
Noda, Y., Kato, T., Kato, A., Nishizawa, H., Miyazaki, J., Ito, M., Terasawa, S., Sekiya, T., Fujii, T., & Kurahashi, H. (2018) · Congenital Anomalies · doi:10.1111/cga.12302 · Cited by 2
Zhou, F., Liu, S., & Wang, H. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.09.015 · Cited by 2
Du, M., He, Y., Chen, J., Sun, H., Fu, Y., & Wang, J. (2020) · Talanta · doi:10.1016/j.talanta.2020.121035 · Cited by 2
Prenatal Tarama Testleri ve Hücreden Bağımsız Fetal DNA
Şirin, F. B. (2019) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.605545 · Cited by 5
Patel, S. S., & Dugoff, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53094-1.00009-6 · Cited by 3
White, K. L., Batey, A., & Schmid, M. P. (2021) · Fetal Diagnosis and Therapy · doi:10.1159/000512501 · Cited by 2
Kwan, A. H. W., Zhu, X., Gil, M. M., Kwok, Y. K. Y., Wah, Y. M. I., Hui, S. Y. A., Ting, Y.-H., Law, K. M., Lau, D., Xue, S., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12102439 · Cited by 2
Falco, L. D., Vitiello, G., Savarese, G., Suero, T., Ruggiero, R., Savarese, P., Ianniello, M., Petrillo, N., Bruno, M., Legnante, A., et al. (2023) · Genes · doi:10.3390/genes14030668 · Cited by 2
Noninvasive prenatal testing/screening by circulating cell-free DNA
van Riel, M., Stanley, K. E., & Vermeesch, J. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91380-5.00013-7 · Cited by 3
Performance of Massive Parallel Sequencing-Based Cell-Free DNA Testing in Compromised Pregnancies
Antolín, M., Tarrasó, G., Sánchez‐Durán, M. Á., Plaja, A., Martínez-Cruz, D., Xunclà, M., Castells, N., Carreras, E., Tizzano, E. F., & García‐Arumí, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144007 · Cited by 2
cfDNA screening for trisomy 21 tested in unselected pregnancies
Bahcall, O. G. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3953 · Cited by 2
Screening for Aneuploidy in the Patient With Diabesity: Pearls and Pitfalls
Hopkins, M. K., & Dugoff, L. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000589 · Cited by 2
Lüthgens, K., Binder, A., & Biskup, D. (2016) · Prenatal Diagnosis · doi:10.1002/pd.4854 · Cited by 2
Westin, E. R., Tsao, D., Atay, O., Landry, B. P., Ye, P. P., Chandler-Brown, D. B., Alford, B. D., Hoskovec, J. M., Subramaniam, A., Pawlik, K. M., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21262837 · Cited by 2
Metadata
- Authors
- Norton, M. E., Jacobsson, B., Swamy, G. K., Laurent, L. C., Ranzini, A. C., Brar, H., Tomlinson, M. W., Pereira, L., Spitz, J. L., Hollemon, D., Cuckle, H., Musci, T. J., & Wapner, R. J.
- Affiliations
- Saint Peter's University Hospital (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of California San Diego (US)
- Oregon Health & Science University (US)
- Perinatal Quality Foundation (US)
- Columbia University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-23
- Volume
- 372
- Issue
- 17
- Pages
- 1589-1597
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139926668
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 33 · 2025: 39 · 2024: 50 · 2023: 59 · 2022: 61 · 2021: 86 · 2020: 72 · 2019: 74 · 2018: 73 · 2017: 86 · 2016: 107 · 2015: 75
- FWCI
- 113.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Västra Götalandsregionen
- Thomas Jefferson University
- University of California, San Diego
- University of California, San Francisco
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
- Health Sciences › Medicine › Obstetrics and Gynecology › Maternal and Perinatal Health Interventions
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Assisted Reproductive Technology and Twin Pregnancy
- Keywords
- cell-free DNA, prenatal aneuploidy screening, Down syndrome, trisomy 18, trisomy 13, first-trimester screening, nuchal translucency, biochemical analytes, diagnostic accuracy, false positive rate, positive predictive value, non-invasive prenatal testing, maternal age
- MeSH terms
- Adolescent, Adult, Chromosome Aberrations, DNA, Down Syndrome, False Positive Reactions, Female, Fetus, Humans, Middle Aged, Pregnancy, Pregnancy Trimester, First, Prenatal Diagnosis, Prospective Studies, Sensitivity and Specificity, Single-Blind Method, Area Under Curve, Nuchal Translucency Measurement, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.